YaoGeJu

Company directoryChina company filings

Hubei Guangji Pharmaceutical Co.,Ltd.

As of 18 November 2026, for the company name Hubei Guangji Pharmaceutical Co.,Ltd. as recorded, the chemical-drug catalogue lists 4 active records with this name as holder; 8 active API registrations list this name as first registered company.

Check drug filings and source records for this company-name string.

Listed by the company name as recorded in the source, without merging affiliated entities.

Page reference

CDE data as of
2026/11/18
Matching scope
Loaded public-source records only

These counts cover loaded acceptance records only. First-applicant and co-applicant counts are not added together. CDE data as of 2026/11/18.

Drug filings

11 acceptance records as first applicant, grouped into 8 source drug names. Source data as of 2026/11/18.

This source was last successfully updated at 2026/11/18; current coverage may be incomplete.

Acceptance records are de-duplicated by acceptance number. Drug names are normalized only for width and whitespace; dosage forms and combinations remain separate. Application types are retained from the source. Expand a drug to inspect each record. Published drugs link to their drug pages; other names do not create new public drug pages.

Ceftazidime And Avibactam Sodium For Injection 1 records · Latest accepted 2026/08/03

Generic · 1

Drug filings
Acceptance numberApplication typeAcceptedCompany / applicantView source
CYHS2601870Generic2026/08/03Hubei Guangji Pharmaceutical Co.,Ltd.; Shandong Lukang Pharmaceutical Co.,Ltd.CDE ↗
Moxifloxacin Hydrochloride And Sodium Chloride Injection 2 records · Latest accepted 2026/06/11

Generic · 2

Drug filings
Acceptance numberApplication typeAcceptedCompany / applicantView source
CYHS2601381Generic2026/06/11Hubei Guangji Pharmaceutical Co.,Ltd.; Wuhan Fu Xing Bio Pharma Co., Ltd. romanizedCDE ↗
CYHS2403132Generic2024/09/20Hubei Guangji Pharmaceutical Co.,Ltd.; Wuhan Fu Xing Bio Pharma Co., Ltd. romanizedCDE ↗
Dapagliflozin Tablets 2 records · Latest accepted 2026/04/23

Generic · 2

Drug filings
Acceptance numberApplication typeAcceptedCompany / applicantView source
CYHS2600934Generic2026/04/23Hubei Guangji Pharmaceutical Co.,Ltd.CDE ↗
CYHS2600933Generic2026/04/23Hubei Guangji Pharmaceutical Co.,Ltd.CDE ↗
维生素B6注射液 · No verified English name 1 records · Latest accepted 2024/12/24

Generic · 1

Drug filings
Acceptance numberApplication typeAcceptedCompany / applicantView source
CYHS2404486Generic2024/12/24Hubei Guangji Pharmaceutical Co.,Ltd.; Lang Tian Pharma (Hubei) Co., Ltd. romanizedCDE ↗
Mecobalamin Tablets 1 records · Latest accepted 2024/08/27

Generic · 1

Drug filings
Acceptance numberApplication typeAcceptedCompany / applicantView source
CYHS2402791Generic2024/08/27Hubei Guangji Pharmaceutical Co.,Ltd.CDE ↗
Valacyclovir Hydrochloride Tablets 1 records · Latest accepted 2024/01/11

Supplement · 1

Drug filings
Acceptance numberApplication typeAcceptedCompany / applicantView source
CYHB2450037Supplement2024/01/11Hubei Guangji Pharmaceutical Co.,Ltd.CDE ↗
Febuxostat Tablets 2 records · Latest accepted 2023/10/21

Generic · 2

Drug filings
Acceptance numberApplication typeAcceptedCompany / applicantView source
CYHS2302825Generic2023/10/21Hubei Guangji Pharmaceutical Co.,Ltd.CDE ↗
CYHS2302824Generic2023/10/21Hubei Guangji Pharmaceutical Co.,Ltd.CDE ↗
Pantoprazole Enteric-Coated Tablets 1 records · Latest accepted 2023/04/22

Supplement · 1

Drug filings
Acceptance numberApplication typeAcceptedCompany / applicantView source
CYHB2350377Supplement2023/04/22Hubei Guangji Pharmaceutical Co.,Ltd.CDE ↗

Changes in the last 90 days

1 events from 2026/08/22 to 2026/11/19. CDE data as of 2026/11/18; NMPA data as of 2026/11/19.

This source was last successfully updated at 2026/11/18; current coverage may be incomplete.

Last 90 days, ordered by fact date. Marketing approvals, trial registrations, supplements, notices and review changes are labelled separately. Fact dates are approval dates, acceptance dates, trial first-publication dates, or the date an application stopped being listed as under review. Publication dates and dates added to this site are listed separately. Historical records with earlier dates are not current-period new events. Exit records cover currently inactive applications whose delisting date is known, not a full review history.

No longer listed under review: 1 application

  1. 2026/11/12No longer listed under review

    维生素B6注射液 · No verified English name

    CYHS2404486

    Fact date: 2026/11/12 · Date added to this site: 2026/11/12

    Accepted: 2024/12/24

    no longer on the CDE under-review list as of the data cut-off; the review / approval outcome is to be checked

    View source ↗

Under review

4 acceptance numbers with this company as first applicant are currently listed as under review by CDE. Source data as of 2026/11/18.

This source was last successfully updated at 2026/11/18; current coverage may be incomplete.

Under review
Drug Acceptance numberApplication typeAcceptedCompany / applicantView source
Ceftazidime And Avibactam Sodium For Injection CYHS2601870Generic2026/08/03Hubei Guangji Pharmaceutical Co.,Ltd.; Shandong Lukang Pharmaceutical Co.,Ltd.CDE ↗
Moxifloxacin Hydrochloride And Sodium Chloride Injection CYHS2601381Generic2026/06/11Hubei Guangji Pharmaceutical Co.,Ltd.; Wuhan Fu Xing Bio Pharma Co., Ltd. romanizedCDE ↗
Dapagliflozin Tablets CYHS2600934Generic2026/04/23Hubei Guangji Pharmaceutical Co.,Ltd.CDE ↗
Dapagliflozin Tablets CYHS2600933Generic2026/04/23Hubei Guangji Pharmaceutical Co.,Ltd.CDE ↗

Catalogue holder records

4 loaded active catalogue records whose holder name matches this source company name. Source data as of 2026/11/18. Manufacturer-only records are excluded.

DrugMarketing authorization holderManufacturerApproval numberApprovedCatalogue category (source text)View source
Febuxostat TabletsHubei Guangji Pharmaceutical Co.,Ltd.Hubei Guangji Pharmaceutical Co.,Ltd.国药准字H202498472024/12/25Not stated by sourceCDE ↗
Febuxostat TabletsHubei Guangji Pharmaceutical Co.,Ltd.Hubei Guangji Pharmaceutical Co.,Ltd.国药准字H202498482024/12/25Not stated by sourceCDE ↗
Valacyclovir Hydrochloride TabletsHubei Guangji Pharmaceutical Co.,Ltd.Hubei Guangji Pharmaceutical Co.,Ltd.国药准字H202473162024/12/12Drug that passed quality-and-efficacy consistency evaluationCDE ↗
Tinidazole TabletsHubei Guangji Pharmaceutical Co.,Ltd.Hubei Guangji Pharmaceutical Co.,Ltd.国药准字H109501512020/12/17Drug that passed quality-and-efficacy consistency evaluationCDE ↗

Only active catalogue records matching the source holder name are listed. A manufacturer role does not count as a holder record. The catalogue covers only part of the chemical-drug market; source categories do not establish complete market coverage or qualifications.

API registrations

8 loaded active API registrations whose first registered company matches this source company name. Source data as of 2026/11/18.

NameCompany / applicantRegistration numberStatusSource update dateView source
核黄素磷酸钠 · No verified English nameHubei Guangji Pharmaceutical Co.,Ltd.Y20210001259A2024/02/08CDE ↗
维生素B2 · No verified English nameHubei Guangji Pharmaceutical Co.,Ltd.Y20190008557A2025/06/13CDE ↗
核黄素磷酸钠 · No verified English nameHubei Guangji Pharmaceutical Co.,Ltd.Y20190008554A2025/06/13CDE ↗
替硝唑 · No verified English nameHubei Guangji Pharmaceutical Co.,Ltd.Y20190006914A2023/03/24CDE ↗
贝诺酯 · No verified English nameHubei Guangji Pharmaceutical Co.,Ltd.Y20190001219A—CDE ↗
利奈唑胺 · No verified English nameHubei Guangji Pharmaceutical Co.,Ltd.Y20180000965A2023/07/28CDE ↗
阿托伐他汀钙 · No verified English nameHubei Guangji Pharmaceutical Co.,Ltd.Y20170000417I—CDE ↗
恩替卡韦 · No verified English nameHubei Guangji Pharmaceutical Co.,Ltd.Y20170000288A2023/10/19CDE ↗

Only loaded active API registrations not listed as cancelled are shown. A/I are source registration statuses. Records are listed by registration number and do not establish capacity or supply. The register does not identify the associated formulation.

Co-applicant records

3 acceptance records name this company after the first applicant. They are listed separately and are not included in first-applicant drug or filing counts. Source data as of 2026/11/18.

This source was last successfully updated at 2026/11/18; current coverage may be incomplete.

Co-applicant records
Drug Acceptance numberApplication typeAcceptedCompany / applicantView source
Mecobalamin Tablets CYHS2601428Generic2026/06/16Hubei Chang Jiang Rui Yi Pharmaceuticals Technology Co., Ltd. romanized; Hubei Guangji Pharmaceutical Co.,Ltd.CDE ↗
Adapalene Gel CYHS2503608Generic2025/10/10Guo Yao Holding Xin Ye (Hubei) Pharmaceuticals Co., Ltd. romanized; Hubei Guangji Pharmaceutical Co.,Ltd.CDE ↗
Mupirocin Ointment CYHS2500704Generic2025/02/12Guo Yao Holding Xin Ye (Hubei) Pharmaceuticals Co., Ltd. romanized; Hubei Guangji Pharmaceutical Co.,Ltd.CDE ↗

How current is each source?

CDE acceptances and review
Last successful update: 2026/11/18 · Current coverage may be incomplete
Chemical-drug catalogue
Last successful update: 2026/11/18
API registrations
Last successful update: 2026/11/18
NMPA drug delivery notices
Last successful update: 2026/11/19

Loaded notices dated 2026-11-05 to 2026-11-19; 0 notices not yet loaded. Covers loaded notices only, not a complete historical approval database.

Listed by the company name as recorded in the source, without merging affiliated entities.

This page summarizes loaded records only. Parent companies, subsidiaries, former names and aliases are not merged. Counts from different sources must not be added together. No loaded record does not establish the absence of a filing or registration. Check original records where coverage is incomplete, an update has failed, or a source lies outside the loaded scope.

Fact dates are approval dates, acceptance dates, trial first-publication dates, or the date an application stopped being listed as under review. Publication dates and dates added to this site are listed separately. Historical records with earlier dates are not current-period new events. Exit records cover currently inactive applications whose delisting date is known, not a full review history.

Drugs with a verified official English name use that name only. Other drug names retain the Chinese source name marked No verified English name; names with a Chinese public page link to that page. Company labels use verified official names, Latin source names, then fixed-rule transliterations marked romanized; Chinese company names are not displayed. Marked unverified drug names and original statutory reference numbers may appear in Chinese.

Legal reference identifiers are retained verbatim. Company labels use official English entries where available, or a visibly marked fixed romanization. Unverified drug names retain the Chinese source name with a No verified English name marker. Other Chinese free text is not displayed; use the source links or source-name columns in CSV exports.